Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 8-K (Current Report)
Date: March 10, 2025
Subject: Announcement of positive topline data from pivotal clinical trials for lorundrostat, a treatment for uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The document does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The Company reported successful outcomes in two pivotal trials evaluating lorundrostat:
- Launch-HTN (Phase 3): A global, randomized, double-blinded, placebo-controlled trial (n=1,083) met its primary endpoint.
- Week 6 (50 mg): Placebo-adjusted reduction in systolic blood pressure of -9.1 mmHg (p<0.0001).
- Week 12 (50 mg): Placebo-adjusted reduction sustained at -11.7 mmHg (p<0.0001).
- Population: Approximately 63% had BMI ≥30kg/m²; 47% women; 29% Black or African American.
- Advance-HTN (Phase 2): A pivotal trial evaluating add-on therapy met its primary endpoint.
- Week 12 (50 mg): Placebo-adjusted reduction in 24-hour average systolic blood pressure of -7.9 mmHg.
- Population: Approximately 66% had BMI ≥30kg/m²; 40% women; 50% Black or African American.
- Safety Profile: Both trials demonstrated a favorable safety and tolerability profile.
- Launch-HTN SAEs: 2.2% in the 50 mg arm vs. 3.0% in the placebo arm.
- Hyperkalemia: Incidence was 1.1% (50 mg) and 1.5% (50-100 mg) in Launch-HTN; 5.3% and 7.4% in Advance-HTN.
Guidance, Outlook, and Risks
Outlook: Management believes the results demonstrate the opportunity for lorundrostat as a third-line or later treatment. The Company expects these trials may serve as the basis for a New Drug Application (NDA) to the FDA. Additional data from the Advance-HTN trial is embargoed until March 29, 2025, for presentation at the American College of Cardiology Scientific Sessions.
Risks and Contingencies:
- Topline results are preliminary and subject to change upon comprehensive review.
- Future performance depends entirely on the success of lorundrostat.
- Regulatory approval is not guaranteed; the FDA may not deem the data sufficient for an NDA.
- Reliance on third parties for manufacturing and testing.
- Potential for unexpected adverse side effects or inadequate efficacy in future studies.
Investor Verification Checklist
- Verify the full statistical analysis of the Launch-HTN and Advance-HTN trials once the complete data is released.
- Monitor the FDA's response to the Company's potential NDA submission based on these pivotal trials.
- Review the detailed safety data for Advance-HTN when presented on March 29, 2025.
- Assess the Company's cash runway and capital requirements, as this filing does not disclose current liquidity.
- Confirm the status of the Transform-HTN open-label extension trial for long-term safety data.